Targeting JAKs is also a reality in RA, such as tofacitinib targeting JAK1, JAK2 and JAK3 to treat RA (Phase III), VX-509 and R-348 targeting JAK3 to treat RA (Phase II) [44]. The gene discussed is JAK2; the disease is rheumatoid arthritis.